Vebreltinib

Small molecule

Also known as APL-101, PLB-1001, CBI-3103, CBT-101

Approvedregulatory verdict

Evidence outlook

Approved: MET exon 14 skipping non-small cell lung cancer (conditional approval) (CN)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

track record: Weak signal

Also in development:Non-Small Cell Lung Cancer with MET Exon 14 Skipping · Phase 3 · investigational in the US

Also approved (3)
CNProduct first approved 2023

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer with MET Exon 14 Skipping
Phase 2/3 (1)
Other / comorbidity
NCT06105619 · Beijing Pearl Biotechnology Limited Liability Company
2018-10-08 – 2026-12-31 · Glioblastoma
What this study did
Phase 2 (11)
Non-Small Cell Lung Cancer
NCT07156604 · Fudan University
2025-09-30 – 2030-09-30 · NSCLC, Neoadjuvant Therapy
What this study did
NCT06644313 · Shanghai Pulmonary Hospital, Shanghai, China
2024-11-01 – 2029-11-01 · Potentially Resectable MET-altered Non-Small Cell Lung Cancer
What this study did
NCT07549061 · Shanghai Chest Hospital
2026-09-03 – 2028-09-01 · NSCLC (Advanced Non-small Cell Lung Cancer)
What this study did
NCT06827145 · National Cancer Center, China
2024-10-14 – 2028-09 · Non-Small-Cell Lung Cancer
What this study did
NCT06574347 · Avistone Biotechnology Co., Ltd.
2024-08-07 – 2027-07-31 · Non-Small-Cell Lung Cancer
What this study did
Non-Small Cell Lung Cancer with MET Exon 14 Skipping
NCT07153770 · Shanghai Pulmonary Hospital, Shanghai, China
2025-09-20 – 2028-09-20 · NSCLC, MET Exon 14 Mutation, MET Activating Mutation
What this study did
NCT03175224 · Apollomics Inc.
2017-09-27 – 2026-11-30 · Solid Tumors, Advanced Cancer, Renal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, NSCLC, Lung Cancer, Brain Tumor, Glioblastoma Multiforme, EGFR Gene Mutation, MET Amplification, HGF, Thyroid Cancer, Pancreatic Cancer, Colon Cancer, MET Alteration, MET Fusion, Exon 14 Skipping
What this study did
Other / comorbidity
NCT06780592 · Huashan Hospital
2025-01-13 – 2027-12-31 · Glioblastoma
What this study did
NCT07153887 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-09-30 – 2027-07-15 · Clear Cell Sarcoma (CCS)
What this study did
NCT06739395 · Tianjin Medical University Second Hospital
2024-11-01 – 2027-05-01 · Solid Tumor, Precision Medicine
What this study did
Phase 1/2 (5)
Non-Small Cell Lung Cancer
NCT04743505 · Washington University School of Medicine
2022-01-18 – 2029-12-31 · Metastatic Non Small Cell Lung Cancer
What this study did
NCT07655622 · Second Affiliated Hospital of Nanchang University
2026-07-03 – 2029-06-03 · Non-Small-Cell Lung Cancer
What this study did
NCT07087223 · Peking University Cancer Hospital & Institute
2025-04-08 – 2028-04 · Non Small Cell Lung Cancer NSCLC
What this study did
NCT06343064 · Avistone Biotechnology Co., Ltd.
2023-06-13 – 2026-12-31 · Non-Small-Cell Lung Cancer
What this study did
Other / comorbidity
NCT03655613 · Apollomics (Australia) Pty. Ltd.
2018-09-05 – 2021-12-15 · Hepatocellular Carcinoma, Renal Cell Carcinoma
What this study did
Phase 1 (3)
Glioma
NCT02978261 · Beijing Pearl Biotechnology Limited Liability Company
2016-09 – 2018-12 · Glioma
What this study did
Non-Small Cell Lung Cancer
NCT02896231 · Beijing Pearl Biotechnology Limited Liability Company
2016-04 – 2019-10 · Non-Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT05367388 · Apollomics Inc.
2022-05-20 – 2022-12 · Bioequivalence
What this study did

Competitive landscape

This mechanism is crowded: 12 other tracked programmes target it, 3 of them ahead of this one.

This drug's own stage for Glioma: Phase 1. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Vebreltinib: this drugPhase 1Small moleculeMETnot yet gradedNo reviewed efficacy summary in this indication
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)not yet gradedNo reviewed efficacy summary in this indication
DordaviproneApprovedSmall moleculeMitochondrial caseinolytic protease P (ClpP), Dopamine D2 receptorWeak signalNo reviewed efficacy summary in this indication
TemozolomideApprovedSmall moleculeDNA alkylation (O6-guanine)Partial signal
NCT00626990: Overall survival: adjuvant temozolomide vs none, median 82.3 vs 46.9 months, hazard ratio 0.64 (95% CI 0.52 to 0.79), p<0.0001; concurrent temozolomide vs none, 66.9 vs 60.4 months, hazard ratio 0.97 (95% CI 0.73 to 1.28), p=0.76 (CT.gov posted results).
TovorafenibApprovedSmall moleculeKinase InhibitorWeak signalNo reviewed efficacy summary in this indication
TrametinibApprovedSmall moleculeMEK1/2not yet gradedNo reviewed efficacy summary in this indication
LuvometinibPhase 3Small moleculeMEK1/2not yet gradedNo reviewed efficacy summary in this indication
SafusidenibPhase 3Small moleculeMutant IDH1not yet gradedNo reviewed efficacy summary in this indication
Abemaciclib (Verzenio)Phase 2Small moleculeCDK4 and CDK6not yet gradedNo reviewed efficacy summary in this indication
OlutasidenibPhase 2Small moleculeMutant IDH1not yet gradedNo reviewed efficacy summary in this indication
CrelosidenibPhase 1Small moleculeMutant IDH1 and IDH2not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(11 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Vebreltinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-31 · NCT06343064 · CT.gov ↗
What to watch
Phase 2Solid Tumor, Precision MedicineRecruiting
Est. primary completion 2026-12-31 · NCT06739395 · CT.gov ↗
What to watch
2027 (7)
January 2027 (1)
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-01-31 · NCT04743505 · CT.gov ↗
What to watch
April 2027 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-04 · NCT07087223 · CT.gov ↗
What to watch
September 2027 (3)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-09-01 · NCT07549061 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-09-20 · NCT07153770 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-09-30 · NCT07156604 · CT.gov ↗
What to watch
December 2027 (2)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-03 · NCT07655622 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT06970782 · CT.gov ↗
What to watch
2029 (2)
February 2029 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-02 · NCT06930794 · CT.gov ↗
What to watch
November 2029 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-11-01 · NCT06644313 · CT.gov ↗
What to watch

See the full readout calendar ↗